Therapeutic inertia in hypertension and dyslipidemia: bridging the evidence-to-action gap
Exploring issues with therapeutic inertia for patients with hypertension and dyslipidemia and the role played by age, physical and cognitive function.
This seminar will consider therapeutic inertia for patients with hypertension and dyslipidemia, looking at problems with initiating, or adjusting therapy, when treatment goals are not being met. Adam will bridge the evidence-to-action gap for therapeutic inertia, and examine the role that age, as well as physical and cognitive function, plays in their treatment gaps.
Speaker
Dr Adam Bress
Dr Adam Bress is an Associate Professor of Population Health Sciences at the University of Utah, a cardiovascular clinical pharmacist and pharmacoepidemiologist. He was selected as one of the University of Utah’s 2024 Presidential Scholars, and his research is focused on the precise, safe, and effective use of medicines to prevent heart disease and dementia.
He has maintained 10 years of continuous NIH-funded research in the prevention and treatment of cardiovascular disease and, more recently, neurodegenerative disease, using state-of-the-art pharmacoepidemiology and pharmacoeconomic methods.
Event notices
- Please note that you can join this event in person or you can join the session remotely.
- Please note that the recording link will be listed on this page when available.
Admission
Contact
Where and when
LSHTM, Keppel Street
London
WC1E 7HT
United Kingdom
Admission
Contact
Events notices
For more information on how we use your data, please see our events privacy notice and our data protection pages.
LSHTM uses third-party platforms, which are not affiliated with LSHTM directly, to host our virtual events. Please see the Zoom privacy notice and Collaborate privacy notice for these.
For any accessibility requirements, please get in touch with the event contact listed above.
